IRVINE, Calif., May 10, 2011 /PRNewswire/ -- Cobalis Corp. (CLSC.PK) announced today they have started airing 60-second television commercials for PreHistin® Allergy Defense Formula, on major national cable and satellite networks across the US.
The commercials, featuring leading US allergist Dr. Paul H. Ratner, MD, explain how PreHistin works at the root cause of allergies, giving seasonal and year-round sufferers the first truly new advance in allergies in many years -- a safe and effective, side-effect free, all natural product intended, in the words of Dr. Ratner, to "help restore a normal response to seasonal and year-round allergies, which is no allergic response at all!"
The commercials were created to help build the PreHistin brand to consumers and allergy sufferers, and drive traffic to the pharmacy retailers across the US who now carry PreHistin in their allergy section. The commercials are now being placed on national cable networks and satellite cable providers, in a planned $5 million TV advertising campaign reaching a daily audience of over 300 million Americans, such as ION, Reelz, Great American Country, Style, Cooking Channel, ABC Family, BBC, BIO, OWN, E!, Lifetime, Oxygen, Soapnet, Womens' Entertainment, Style and many others.
The spots not only present the PreHistin story and explain the real cause of allergies, but prompt viewers that PreHistin is available now at fine pharmacies everywhere, and to "ask your pharmacist for PreHistin today."
Marty Marion, Cobalis CEO said, "We are excited to announce the start of our national TV campaign for PreHistin, which was selected as "Best New Product of 2011" out of a field of over a thousand products at the recent ECRM Cough, Cold and Allergy show. We are committed to supporting those retailers and pharmacies who are selling PreHistin, and television is just one of the support channels we are engaging to drive traffic, stimulate brand awareness and increase sales."
Cobalis President Chas Radovich said, "We believe that when allergy sufferers learn the PreHistin story they will try PreHistin for its ability to naturally restore a normal non-reactive response to allergens with no side effects or sedation. We thank the retailers who have brought PreHistin into their stores, and who are partnering with us to build PreHistin into a national brand."
PreHistin is now on shelves at one of the nation's two largest drugstore chains, as well as many fine regional and local pharmacies, and is expected to be on the shelf at most pharmacy and grocery shelves across the country very quickly.
ABOUT PREHISTIN® ALLERGY DEFENSE FORMULA
PreHistin® Allergy Defense Formula is a patented cobalamin complex that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine. PreHistin is a cherry-flavored lozenge dissolved under the tongue and then swallowed twice a day, usually starting before the allergy season, or taken daily for those suffering from year-round allergies. PreHistin has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications. In clinical trials on thousands of allergy sufferers, PreHistin was shown to be safe and effective in reducing nasal symptoms.
ABOUT COBALIS CORP. -- PREHISTIN®
Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, "The World's First Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin is now available without prescription for both long-term and daily use.
For PreHistin product information please visit http://www.PreHistin.com or call toll free 1-877-4POLLEN (1-877-476-5536). For additional company information please visit the corporate website at http://www.Cobalis.com
16795 Von Karman, Suite 200
Irvine, CA 92606
949-260-0123 (pacific time)
Chas Radovich, President
Martin Marion, CEO
|SOURCE Cobalis Corp.|
Copyright©2010 PR Newswire.
All rights reserved